A Phase 1 interventional study of Tirzepatide and Semaglutide in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 2 sites in Germany. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-03-20.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 8 that started in 2019, is one of 8 in phase 1, and was the 9th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Las Rías Medical Center · Sites in Paraguay
Ages 18–70
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
Matthew J. Budoff · Sites in United States
Ages 40–80
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 17 · Phase 4 10
First in 2016; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 160 across the 43 interventional studies. Of the 29 that completed or were terminated, 25 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 138th largest by enrollment of the 232 interventional ones that give a count, is one of 12 that started in 2019, is one of 76 in phase 1, and was the 148th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing tirzepatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
| NCT07588438Las Rías Medical CenterEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | 2027-08-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a meal. The study will last up to 40 weeks, including a 28-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 15 milligram (mg) tirzepatide administered subcutaneously (SC) once weekly for 28 weeks.
Drug: Tirzepatide
Participants received 1 mg Semaglutide administered SC once weekly for 28 weeks.
Drug: Semaglutide
Participants received Placebo administered SC once weekly for 28 weeks.
Drug: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Administered SC
Change From Baseline in Total Clamp Disposition Index (cDI)
cDI is defined as the product of the M-value derived from the hyperinsulinemic euglycemic clamp over the last 30 minutes and total insulin secretion (ISR AUC0-120min) derived from the insulin secretion rate based on C-peptide using the using the deconvolution technique divided by the total glucose AUC0-120min from the hyperglycemic clamp portion of the study. Least squares (LS) mean was determined by analysis of covariance (ANCOVA) model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment (Type III sum of squares).
Time frame: Baseline, Week 28
Change From Baseline in Fasting Glucose
Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. Fasting glucose was measured prior to standardized mixed-meal tolerance tests (sMMTT). LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
Time frame: Baseline, Week 28
Change From Baseline in Postmeal Glucose
Total AUC from time zero to 240 minutes after start of the meal \[AUC0-240min\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares) and ANOVA model for baseline measures: Variable = Treatment (Type III sum of squares).
Time frame: Baseline, Week 28
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by mixed model repeated measures; (MMRM) model for post-baseline measures: Variable = Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 28
Change From Baseline in Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min)
Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min) will be determined from C-peptide concentrations using the deconvolution technique. LS mean was determined by ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment (Type III sum of squares).
Time frame: Baseline and Week 28
Change From Baseline in Hyperinsulinemic Euglycemic Clamp M-value
Hyperinsulinemic euglycemic clamp M-value is calculated from glucose infusion rate (GIR) over the last 30 minutes, corresponding to steady-state (+150 to +180 minutes), corrected for urine loss and space. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
Time frame: Baseline, Week 28
Change From Baseline in Glucagon Concentration at Fasting
Glucagon concentration was measured prior to sMMTT. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
Time frame: Baseline and Week 28
Change From Baseline in Glucagon Concentration at Postmeal
Total AUC from time zero to 240 minutes after start of the meal \[AUC0-240min\]) during sMMTT. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
Time frame: Baseline and Week 28
Change From Baseline in Food Intake During Ad Libitum Meal
Ad libitum meal served buffet-style. Food intake was recorded during a 45 minute period. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 28
| Milestone | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Started | 45 | 44 | 28 |
| Completed | 41 | 43 | 24 |
| Not completed | 4 | 1 | 4 |
| Withdrew: Adverse event | 1 | 0 | 3 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
cDI is defined as the product of the M-value derived from the hyperinsulinemic euglycemic clamp over the last 30 minutes and total insulin secretion (ISR AUC0-120min) derived from the insulin secretion rate based on C-peptide using the using the deconvolution technique divided by the total glucose AUC0-120min from the hyperglycemic clamp portion of the study. Least squares (LS) mean was determined by analysis of covariance (ANCOVA) model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment (Type III sum of squares).
| pmol*m-2*L*min-2*kg-1 | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Clamp Disposition Index (cDI) | 1.9 ± 0.16 | 1.1 ± 0.10 | 0.0 ± 0.03 |
Fasting glucose is a test to determine sugar levels in blood sample after an overnight fast. Fasting glucose was measured prior to standardized mixed-meal tolerance tests (sMMTT). LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
| milligrams per decilitre (mg/dL) | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Fasting Glucose | -51.4 ± 2.30 | -42.4 ± 2.22 | -4.3 ± 2.98 |
Total AUC from time zero to 240 minutes after start of the meal \[AUC0-240min\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares) and ANOVA model for baseline measures: Variable = Treatment (Type III sum of squares).
| Milligrams per decilitre*minute | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Postmeal Glucose | -17414.0 ± 726.02 | 14236.9 ± 709.53 | 459.2 ± 947.50 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by mixed model repeated measures; (MMRM) model for post-baseline measures: Variable = Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
| % of HbA1c | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | 2.05 ± 0.079 | -1.64 ± 0.078 | 0.29 ± 0.101 |
Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min) will be determined from C-peptide concentrations using the deconvolution technique. LS mean was determined by ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment (Type III sum of squares).
| pmol/min/m^2 | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Insulin Secretion Rate During the 120-Minute Hyperglycemic Clamp (ISR0-120min) | 388.6 ± 20.17 | 286.6 ± 15.82 | 7.4 ± 7.15 |
Hyperinsulinemic euglycemic clamp M-value is calculated from glucose infusion rate (GIR) over the last 30 minutes, corresponding to steady-state (+150 to +180 minutes), corrected for urine loss and space. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
| umol/min/kg [body weight] | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Hyperinsulinemic Euglycemic Clamp M-value | 19.2 ± 1.93 | 10.7 ± 1.99 | -0.6 ± 2.53 |
Glucagon concentration was measured prior to sMMTT. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
| picomoles per litre (pmol/L) | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Glucagon Concentration at Fasting | -3.6 ± 0.55 | -2.8 ± 0.55 | 0.8 ± 0.75 |
Total AUC from time zero to 240 minutes after start of the meal \[AUC0-240min\]) during sMMTT. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Treatment (Type III sum of squares).
| (pmol/L)*min | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Glucagon Concentration at Postmeal | -843.6 ± 86.26 | -502.0 ± 87.33 | -205.9 ± 116.31 |
Ad libitum meal served buffet-style. Food intake was recorded during a 45 minute period. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
| kilocalorie (kcal) | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Food Intake During Ad Libitum Meal | -348.4 ± 34.59 | -284.1 ± 33.94 | -38.6 ± 45.17 |
Collected over Up to Week 32. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/28 (0%) | 2/28 (7.1%) | 18/28 (64.3%) |
| Semaglutide 1 mg | 0/44 (0%) | 0/44 (0%) | 43/44 (97.7%) |
| Tirzepatide 15 mg | 0/45 (0%) | 1/45 (2.2%) | 41/45 (91.1%) |
| Event | Placebo | Semaglutide 1 mg | Tirzepatide 15 mg |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/28 | 0/44 | 0/45 |
| Subacute pancreatitisGastrointestinal disorders | 1/28 | 0/44 | 0/45 |
| UreterolithiasisRenal and urinary disorders | 0/28 | 0/44 | 1/45 |
| Event | Placebo | Semaglutide 1 mg | Tirzepatide 15 mg |
|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 7/28 | 31/44 | 27/45 |
| Injection site haematomaGeneral disorders | 12/28 | 12/44 | 12/45 |
| Early satietyGeneral disorders | 6/28 | 12/44 | 16/45 |
| DyspepsiaGastrointestinal disorders | 2/28 | 14/44 | 3/45 |
| DiarrhoeaGastrointestinal disorders | 6/28 | 13/44 | 9/45 |
| NauseaGastrointestinal disorders | 7/28 | 13/44 | 11/45 |
| FatigueGeneral disorders | 2/28 | 10/44 | 5/45 |
| ConstipationGastrointestinal disorders | 0/28 | 8/44 | 6/45 |
| EructationGastrointestinal disorders | 0/28 | 8/44 | 8/45 |
| NasopharyngitisInfections and infestations | 3/28 | 8/44 | 7/45 |
All randomized participants who received at least one dose of study drug.
| Age, Categorical(Participants) | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 31 | 20 | 18 | 69 |
| >=65 years | 14 | 24 | 10 | 48 |
| Age, Continuous(years) | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 61.1 ± 7.1 | 63.7 ± 5.9 | 60.4 ± 7.6 | 61.9 ± 6.9 |
| Sex: Female, Male(Participants) | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 14 | 10 | 7 | 31 |
| Male | 31 | 34 | 21 | 86 |
| Ethnicity (NIH/OMB)(Participants) | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 45 | 44 | 28 | 117 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 44 | 44 | 28 | 116 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo | Total |
|---|---|---|---|---|
| Germany | 45 | 44 | 28 | 117 |
| HbA1c (%)(percentage) | Tirzepatide 15 mg | Semaglutide 1 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 7.83 ± 0.72 | 7.70 ± 0.60 | 7.90 ± 0.51 | 7.80 ± 0.63 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Apr 2021, 21 months.
Results were first posted in Mar 2023, 1 year 11 months after primary completion.
Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 21 months is above that.
Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide